Our management team has been responsible for the development of the i-body technology platform, including the identification and pre-clinical development of our lead i-body drug candidate. AdAlta’s management team is focused on progressing AD-114 into the clinic.
MANAGING DIRECTOR & CEO
Sam is the founding CEO of AdAlta and has over fifteen years’ experience in business development and commercialisation of early stage scientific technologies. Prior to AdAlta, Sam was the Business Development Director at the Co-operative Research Centre for Diagnostics. Sam has also worked for the biotech start up companies Sensologix Inc and Nephrogenix Pty Ltd and at the University of Queensland’s technology commercialisation companies, Uniquest Pty Ltd and IMBcom Pty Ltd. Sam has a Bachelor of Science, a Masters of Intellectual Property Law and has completed the Australian Institute of Company Directors course.
Michael Foley PhD
Mick is the founding scientist of AdAlta and a key inventor of AdAlta’s lead i-body candidate AD-114. Upon completion of his PhD he was awarded a Wellcome Training Fellowship and worked at the Walter and Elisa Hall Institute. In 1995 Mick was awarded an ARC QEII Fellowship where he established the phage display of antibodies and peptide technology as a means of answering fundamental questions of immunity to infectious diseases. Mick is an internationally recognized leader in phage display, the technology used to screen the i-body library to identify new drug candidates. Having published over 70 scientific publications Mick has received funding from ARC, NHMRC and NIH (US).